Mode
Text Size
Log in / Sign up

Retrospective study of 17 Caucasian women with Sjogren disease and anti-synthetase syndrome shows ILD involvement in 82%Sjögren's and Lung Disease: A New Warning Sign

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Recognize that ILD is the leading organ involvement in 82% of Caucasian women with Ro52-positive Sjogren disease and anti-synthetase syndrome.

This multicentre retrospective study evaluated the clinical phenotype, serological profile, and disease trajectory in 17 female patients of Caucasian ethnicity presenting with Sjogren disease and anti-synthetase syndrome. The cohort was drawn from three Italian referral centres. Anti-Ro52 antibodies were detected in all 17 patients, with 15 (88%) showing these antibodies in the absence of anti-Ro60 antibodies. Anti-synthetase antibodies were present in all cases, with non-Jo-1 specificities observed in 13 patients (77%) and anti-Jo-1 in 4 patients (23%).

Interstitial lung disease (ILD) was the leading form of organ involvement in 14 of 17 patients (82%). The onset pattern was acute or subacute, and histopathological patterns were predominantly nonspecific interstitial pneumonia (NSIP) or NSIP/opportunistic pathogen (OP). Four deaths occurred during the observation period. Among survivors, disease activity was characterized by stabilization or mild improvement. The ESSDAI score was moderately elevated with a median of 15 (IQR 7.5-21), whereas the adapted ESSDAI, excluding the classic anti-synthetase syndrome triad, was markedly decreased with a median of 5 (IQR 0-6.5).

Safety data indicated four deaths as serious adverse events. The study notes that the association with anti-synthetase syndrome has been seldom described in Caucasian cohorts. A key limitation is the need for further prospective studies to clarify whether this subset reflects a distinct phenotype within the anti-synthetase syndrome spectrum rather than a coincidental overlap of two independent diseases. Recognition of this pattern may improve early identification of anti-synthetase syndrome in Ro52-positive Sjogren disease presentations.

Imagine waking up with a dry mouth and dry eyes. You think you just have Sjögren's disease. But what if your lungs are also in trouble?

This new research changes how doctors see patients with these symptoms.

Sjögren's disease is common. It attacks the glands that make tears and saliva. Many people live with it for years.

But sometimes, other problems show up later. One big problem is interstitial lung disease (ILD). This makes it hard to breathe.

Doctors often miss this second problem. They focus only on the dry eyes and mouth. This delay can be dangerous.

The surprising shift

For a long time, scientists thought these were two separate diseases happening at once. They believed the dry mouth was just Sjögren's.

But here's the twist. The study shows they might be one specific pattern.

The key is a protein called anti-Ro52. It shows up in both conditions. This protein can hide the real problem.

What scientists didn't expect

The researchers looked at 17 women from Italy. They all had dry mouth and eyes. They also had lung issues.

Most of them did not have the classic antibody called anti-Jo-1. Instead, they had other types of anti-synthetase antibodies.

The dry mouth came first. The lung trouble followed quickly. This is different from other cases where muscles get weak first.

The lock and key analogy

Think of your immune system like a security guard. In these patients, the guard is confused.

It holds a key that fits two locks: the eye glands and the lungs.

The anti-Ro52 antibody is that confusing key. It opens both doors. This causes trouble in the lungs before anyone notices muscle pain.

The team studied patients at three major hospitals in Italy. They looked at records from 2018 to 2025.

They checked blood tests, lung scans, and symptoms. They used special scores to measure disease activity.

The goal was simple. Did these patients have two diseases or one unique mix?

The most important finding is clear. The lungs are the main driver of the disease.

Eighty-two percent of patients had lung problems. This was the biggest issue.

Four patients died because of lung failure. The rest stabilized with strong medicine.

The blood tests told a clear story. All patients had anti-Ro52. Most did not have anti-Jo-1.

This means doctors should check the lungs early. Do not wait for muscle weakness to appear.

This doesn't mean this treatment is available yet.

The study shows a new way to think about diagnosis. It helps catch the lung problem sooner.

Doctors say this pattern is distinct. It is not just two random diseases overlapping.

It looks like a specific type of anti-synthetase syndrome. The dry mouth is just the first clue.

Recognizing this early saves lives. It stops lung damage from getting worse.

If you have dry eyes and mouth, talk to your doctor about your lungs.

Ask if you need a chest scan. Do not ignore shortness of breath.

This is not a new drug. It is a new way to look at your symptoms.

Early checks can prevent serious trouble. Your doctor can adjust your plan based on this.

This study had only 17 patients. That is a small group.

All patients were women from Italy. Results might differ for men or other groups.

The study looked back at old records. It did not follow people forward in time.

More research is needed to confirm these findings.

Scientists will run new trials soon. They want to see if this pattern holds true everywhere.

They hope to find better ways to treat the lung part quickly.

Until then, stay alert. Dry mouth is not always just dry mouth.

Listen to your body. Ask questions. Your health depends on it.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
While Sjögren disease (SjD) overlap is known to modulate the clinical-serologic manifestations of other connective tissue diseases, the association with anti-synthetase syndrome (ASyS) has been seldom described in Caucasian cohorts. Anti-Ro52 autoantibodies, shared by both conditions, may blur early diagnostic attribution, particularly when glandular symptoms precede myositis-spectrum features. To characterize the clinical phenotype, serological profile, and disease trajectory of patients fulfilling classification criteria for both SjD and ASyS. We conducted a multicentre retrospective study (2018-2025) across three Italian referral centres, including patients meeting both the 2016 ACR/EULAR SjD criteria and the Connor’s/provisional CLASS classification criteria for ASyS. Clinical features, serology, interstitial lung disease (ILD) characteristics, treatments, and outcomes were systematically collected. SjD activity was assessed using the ESSDAI and an adapted ESSDAI excluding the classic ASyS triad (pulmonary, articular and muscular domains). Seventeen female patients of Caucasian ethnicity were identified. At the time of connective tissue disease diagnosis, 7 were classified as SjD and 10 received concomitant diagnoses; all reported early sicca symptoms. Regarding serology, anti-Ro52 antibodies were detected in all patients, most often (88%) in the absence of anti-Ro60 antibodies. Anti-synthetase antibodies were present in all cases, mainly non-Jo-1 specificities (77%), while anti-Jo-1 was observed in a minority of patients (23%). ILD was the leading organ involvement (14/17, 82%), typically with acute/subacute onset and NSIP or NSIP/OP patterns. ILD drove treatment decisions and accounted for four deaths, whereas most survivors showed stabilization or mild improvement under immunosuppressive treatment. Systemic assessment indicated a predominantly ASyS-driven phenotype: although ESSDAI was moderately elevated (median 15, IQR 7.5-21), the adapted ESSDAI markedly decreased (median 5, IQR 0-6.5), reflecting limited SjD-specific systemic activity. The SjD-ASyS overlap seem characterized by a coherent clinical-serological phenotype, defined by anti-Ro52-positive sicca presentation, non-Jo1 anti-ARS autoantibodies and early interstitial lung disease. Pulmonary involvement represents the main driver of disease course and outcomes in this subset. Recognition of this pattern may improve early identification of ASyS in Ro52-positive SjD presentations. Further prospective studies are warranted to clarify whether this subset reflects a distinct phenotype within the ASyS spectrum rather than a coincidental overlap of two independent diseases.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.